Market Overview

Report: uniQure Could Put Itself Up For Sale

Report: uniQure Could Put Itself Up For Sale

uniQure NV (NASDAQ: QURE) shares are trading higher by 6% in Monday's pre-market session following a Bloomberg report the company is exploring strategic options, including a potential sale.

uniQure is a gene therapy company exploring options amid interest from other pharmaceutical companies looking to expand in gene therapy.

The stock traded around $76.80 per share at time of publication after closing Friday at $72.55. The stock's 52-week higher is $78.02 and its 52-week low is $21.89.

Related Links:

6 Gene Therapy M&A Targets On The Radar

Sorrento Therapeutics Could IPO Its Scilex Unit

Posted-In: News Rumors Media


Related Articles (QURE)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Report: Apple Has Eye On Gold Statues With Movie Developments

Scoop: Shopify And ParcelPal To Integrate For Cannabis Delivery In Canada